Market Overview

UPDATE: Bank of America Raises PO to $7 on Arena Pharmaceuticals on Lorcaserin Aproval

Share:
Related ARNA
Smoke Rising: As More States Legalize, Marijuana Investing Opportunity Grows
Watch These 5 Huge Call Purchases In Thursday Trade
Healthcare bounces back from Trump tantrum (Seeking Alpha)

Bank of America reiterates its Underperform rating on Arena Pharmaceuticals (NASDAQ: ARNA) but raises its price target from $5 to $7.

Bank of America comments, "Following FDA approval of ARNA's obesity drug lorcaserin (trade name Belviq), we raised our NPV to $7/sh (from $5). Our caution on the stock has been due to a combination of delay expectations and a modest market opportunity. This latter concern is unchanged based on the drug's marginal efficacy (3-4% PBO-adjusted weight loss) and various safety concerns. With an EV of $2.3bn versus $2.5bn for VVUS, we view ARNA's current valuation as rich and remain Underperform."

ARNA closed at $11.39 on Wednesday.

Latest Ratings for ARNA

DateFirmActionFromTo
Sep 2016FBR CapitalInitiates Coverage onOutperform
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & Co.Initiates Coverage onMarket Perform

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!